Status:
COMPLETED
Study of Omalizumab in Moderate to Severe Bronchial Asthma
Lead Sponsor:
Novartis
Collaborating Sponsors:
Daiichi Sankyo Co., Ltd.
Conditions:
Asthma
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
Eligibility Criteria
Inclusion
- Allergic asthma patients
- Inadequately controlled patients
Exclusion
- \- History of severe anaphylactoid or anaphylactic reactions
- Previous treatment with omalizumab
- History of cancer or cancer
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
327 Patients enrolled
Trial Details
Trial ID
NCT00232050
Start Date
October 1 2002
End Date
May 1 2005
Last Update
October 25 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.